Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels
- 1 June 1997
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 15 (2) , 115-121
- https://doi.org/10.1023/a:1005817024382
Abstract
Gemcitabine (GEM) is a novel nucleoside analogue with a unique mechanism of action. Preliminary studies have shown a mild, schedule-dependent toxic profile with a broad range of MTDs and promising...Keywords
This publication has 13 references indexed in Scilit:
- A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancerBritish Journal of Cancer, 1996
- Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumorsCancer Chemotherapy and Pharmacology, 1996
- Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumoursBiochemical Pharmacology, 1994
- Weekly gemcitabine in advanced or metastatic solid tumorsInvestigational New Drugs, 1994
- Clinical and preclinical activity of 2′,2′- difluorodeoxycytidine (gemcitabine)Cancer Treatment Reviews, 1993
- Difluorodeoxycytidine (dFdC) — gemcitabine: A phase I studyInvestigational New Drugs, 1992
- Saturation of 2?, 2?-difluorodeoxycytidine 5?-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabineCancer Chemotherapy and Pharmacology, 1991
- The calculation of received dose intensity.Journal of Clinical Oncology, 1990
- PHARMACOLOGICALLY DIRECTED DESIGN OF THE DOSE-RATE AND SCHEDULE OF 2',2'-DIFLUORODEOXYCYTIDINE (GEMCITABINE) ADMINISTRATION IN LEUKEMIA1990
- Reporting results of cancer treatmentCancer, 1981